A Phase 1, Open-Label, Drug Interaction Study to Assess Safety, Tolerability, and Pharmacokinetics of Co-Administered Miravirsen and Telaprevir in Healthy Subjects
Latest Information Update: 28 Oct 2015
Price :
$35 *
At a glance
- Drugs Miravirsen (Primary) ; Telaprevir
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jul 2012 New trial record